GoldState Music | $500,000,000 | (Apr 22, 2025)
CSignum | $8,021,670 | (Apr 22, 2025)
Terra Security | $7,500,000 | (Apr 22, 2025)
Foresight Diagnostics Inc.
United States
- Aurora, CO
- 28/04/2023
- Series B
- $58,750,000
Foresight Diagnostics is a precision medicine company developing a novel liquid biopsy test for the measurement of minimal residual disease (MRD) for aid in patient management that is funded by leading diagnostics VC firms in Silicon Valley. Foresight’s cell-free DNA testing platform was developed in the labs of two prominent professors at Stanford University and is backed by several major peer-reviewed publications. The company has garnered significant partnering interest from multiple pharmaceutical companies in oncology and is poised for rapid growth. Foresight Diagnostics is headquartered in Aurora, Colorado.
- Industry Biotechnology Research
- Website https://www.foresight-dx.com/
- LinkedIn https://www.linkedin.com/company/foresight-diagnostics-inc/
Related People
Jake ChabonCo Founder
United States -
Denver, Colorado
I am molecular biologist and bioinformatic scientist with a passion for entrepreneurship. I completed my graduate and postdoctoral training at Stanford University where my research was focused on developing novel blood based cancer diagnostic assays. I am now the CEO & Co-founder of Foresight Diagnostics, a venture-backed molecular diagnostics company that is developing non-invasive cancer detection technologies. Foresight’s unique cell-free DNA testing platform enables the ultra-sensitive detection of tumor-derived DNA in the bloodstream, leading to more personalized and effective cancer treatment strategies for patients.
Brellium | $13,700,000 | (Apr 22, 2025)
Spur | $4,500,000 | (Apr 22, 2025)
Cosmic Robotics | $4,000,000 | (Apr 22, 2025)
Capsule | $12,000,000 | (Apr 22, 2025)
Kenzo Security | $45,000,000 | (Apr 22, 2025)
Electra.aero | $115,000,000 | (Apr 22, 2025)
ROH | $9,000,000 | (Apr 22, 2025)
Booked it | $3,316,375 | (Apr 18, 2025)
Exaforce Inc. | $75,000,000 | (Apr 18, 2025)